

# Cognition in Cancer Survivorship

April 25, 2024

**Christopher G. Manschreck, MD**

Assistant Professor

Division of Behavioral Health Consultation and Integration

Department of Psychiatry and Behavioral Sciences

University of New Mexico School of Medicine

No conflicts of interest to disclose.

# Overview

- Cancer Survivorship
- Cognition and Neurocognitive Disorders
- Cancer and Cognition
- Clinical Considerations

# Learning Objectives:


1. Describe evidence for the phenomenon of Cancer-Related Cognitive Impairment
2. Describe how to respond to cognitive symptom reports in cancer survivors.

# Survivorship

# Survivorship Today

## Present and future

- 2022 – 18.1 million cancer survivors in US
- Currently 12.5 million survivors living 5+ years after dx. (nearly 4% of US pop.)
- Projected next decade growth of 5+ year cancer survivors to 16.3 million



# Cognition

# Cognition in the Clinic

- **cognition** refers to processes of perceiving, evaluating, recalling and responding to sensory input.
- In practice cognitive ability is evaluated in terms of **domains of cognition**.



# Cognition in the Clinic

## ■ Domains of cognition (each w/subdomains)

Sensation

Perception

Motor skills and construction

Attention and concentration

Memory

Executive functioning

Processing speed

Language/verbal skills


Social Cognition



# Cognition in the Clinic: Neurocognitive Disorders


Severity is stratified by **functional impairment of IADL and ADL:**

- **Mild:** Difficulties with instrumental activities of daily living (e.g., housework, managing money).
- **Moderate:** Difficulties with basic activities of daily living (e.g., feeding, dressing).
- **Severe:** Fully dependent.



# Cognition in the Clinic: Gold Standard for Evaluation

- Neuropsychologists perform **neuropsychological testing (NPT)**
  - a standardized battery of neuropsychological tests to characterize deficits in specific cognitive domains/subdomains.
  - Includes a summative evaluation of deficits and capabilities
- In some areas, NPT may be difficult to access, so clinical measures of cognition may have to suffice.



# Cognition in the Clinic: Quantified clinical assessment of cognition

- Mini Mental Status Evaluation (MMSE)
  - MiniCOG
  - Montreal Cognitive Assessment (MoCA)
  - Saint Louis University Mental Status (SLUMS)
  - Freund Clock Draw
- 
- Note each test evaluates specific cognitive domains/subdomains.
  - MoCA and SLUMS preferred for sensitivity to mild cognitive impairment.

The image shows a sample of the Montreal Cognitive Assessment (MoCA) form. It includes a grid for drawing a cube, a series of numbers for a trail test, and three animal drawings (lion, elephant, camel) for a naming task. Below these are sections for 'Clock Drawing' and 'Mini-Mental State Examination' with various subtests and a final score of 28/30.

# Cognition and Cancer

# Cancer and Cognition

## Cancer related cognitive impairment?

- Subjective cognitive slowing and cognitive dysfunction is commonly noted by cancer survivors
  - Described as “brain-fog” or “chemo-brain” by survivors
  - Survivors typically attribute to chemotherapy
  - Current term: Cancer-related cognitive impairment (CRCI)
- What do we know about this phenomenon?

# Cancer and Cognition

## Mirage or oasis?

- Investigations confirm that **cancer survivors report subjective cognitive problems more frequently** than general population:
  - **Jean-Pierre, et al. 2011:** Analyzed data from National Health and Nutrition Examination Survey (NHANES) N=9819, hx cancer n=1305
  - 14% percent of those with cancer, and 8% of those without, noted past year memory symptoms
  - controlling for demographics, **respondents with cancer were 40% more likely to report memory symptoms** (95% CI, 1.08 to 1.83)
- ALSO... Cancer survivors report **more perceived functional deficits.** (Lange et al. 2019)

# Cancer and Cognition

## Mirage or oasis?

- Correlation between cognitive symptoms and objective impairment.
  - **Dhillon et al. 2018:** Performed neuropsychological testing and administered the FACT-COG (self-report of cognitive impairment) in 362 Australian patients with CRC (localized dz: 289: chemo: 173)
  - Findings: Symptoms did not correlate with cognitive performance.



# Cancer and Cognition

## Mirage or Oasis?

- The mixed results correlating symptoms to impairments prompted the presumption that other factors may driving cognitive complaints
  - Pain
  - Insomnia
  - Fatigue
  - depression and anxiety



# Cancer and Cognition

## Mirage or oasis?

- Chemotherapy studies **show strong consistent evidence of cognitive performance deficits.**
- Some evidence for **cognitive recovery**



# Cancer and Cognition

## Representative studies of chemotherapy on cognition.

Study	Patients, control group Age	Cognitive assessment	Main CT type (% of patients)	Main outcome
Collins et al.	Breast cancer (n=56, 52 years old $\pm$ 7.8) versus HC (n=56)	Before, shortly after and 1-year post-CT	FEC-T: 70%	Significant rate of decline to baseline from 1-year post-CT in patients. - 48% of patients had decreased shortly post-CT (9% HC). - <b>Significant rebound from short-term and 1-year post-CT</b>
Wouters et al.	Lymphoma (n=106, 47 years old $\pm$ 12.6) versus HC (n=53)	After CT (median months since completion: 54.5)	CHOP/MOPP-ABV : 76%	Patients: <b>cognitive impairment in 16%</b> (most effected were those with lower education and pre-morbid IQ)
Hess et al.	Ovarian cancer (n=231, 40–79 years old)	Before CT, before cycle 4, after cycle 6, and 6 months after completion of primary CT	Palitaxel/carboplatin	At cycle 4: <b>25% of patients had cognitive impairment</b> in at least one domain, 21% and 18% at cycle 6- and 6-months post-CT, respectively

# Cancer and Cognition

## Brain imaging

### Chemotherapy in BC:

- Total brain volume reductions
- Loss of gray matter vol.
- White matter microstructural changes

Koppelmans, 2012



# Cancer and Cognition


## Deficits and Risk Factors

Most common deficits in CRCI

- Memory – working most affected
- Attention
- Executive function
- Processing speed

Risk factors

- Age
- Preexisting NCD



# Cancer and Cognition

Chemotherapies most frequently associated with CRCI

- Doxorubicin
- Paclitaxel
- Methotrexate
- 5-Fluorouracil

## **Proposed mechanisms:**

- Disruption of neurogenesis
- Disruption of myelination and oligodendrocyte function
- Mitochondrial damage
- Increased peripheral and brain cytokine production

# Cancer and Cognition

## Outstanding questions


What about other therapies?

- **Hormone therapy**
  - Breast
  - Prostate
- **Targeted therapies/Immunotherapy**
- **Surgery**
- **Radiation therapies**

# Cancer and Cognition

## Outstanding questions

- **Direct effects of cancer on cognition** – non-CNS dz.
  - Breast cancer patients may have increased cognitive impairment **before** treatment. (Ahles et al. 2008)
- What explains **poor overall correlation between survivor symptoms and cognitive performance**?
  - fMRI studies suggest **cognitive adaptation** (recruitment of secondary capabilities into functional networks).





# Cognition and Cancer: Clinical Considerations

# Cancer and Cognition - Clinical Case:

- A 63-year-old female, recently retired schoolteacher, with a PMH of HLD, well controlled asthma and recently discovered R BC (s/p local resection with LNB showing stage IA ER+/Her2 neg dz) **presents after surgery with no new symptoms to plan treatment.**
- **Pre-treatment**
  - inform about cognitive risks (particularly dt chemotherapy, HT ?)
  - Consider cognitive testing in select patients based on risk/distress?

# Cancer and Cognition - Clinical Case:

- A 63-year-old female, recently retired schoolteacher, with a PMH of HLD, well controlled asthma and recently discovered R BC (s/p local resection with LNB showing stage IA ER+/Her2 neg dz, s/p 6 cycles of TAC, NED on most 3/6-month imaging) presents 1 year later with complaints of fatigue, anxiety, and cognitive slowing.

# Cancer and Cognition: Clinical Considerations:

## Clinical considerations:

Responding to patient concerns about cognitive symptoms

- rule out other actionable causes
  - CNS metastasis
  - Rapidly progressive neurocognitive disorders (e.g. prion dz, etc.)
  - Substance use
  - Medications/polypharmacy
  - Nutritional deficiencies
  - Insomnia / fatigue
  - Uncontrolled pain
  - Psychosocial stressors/psychiatric disorders



### Red flags:

- Rapid cognitive decline
- Acute confusion/disorientation
- weight loss, night sweats etc.
- substance use

# Cancer and Cognition: Clinical Considerations:

- Consider clinical cognitive testing (e.g. MoCA, SLUMS) to evaluate extent of impairment.
- Those with more significant cognitive impairment that affects social or occupational function may benefit from formal neuropsychological testing.

# Cancer and Cognition: Clinical Considerations:

## Interventions for CRCI:

- **Pharmacological** - research is at an early stage, with few large RCT and lacking consistent definitions of CRCI cases
  - Agents studied: methylphenidate, modafinil, donepezil, memantine, ginkgo biloba, cotinine erythropoietin.

# Cancer and Cognition: Clinical Considerations:

## Clinical Considerations

What can providers recommend to patients experiencing CRCI?

- **non-pharmacological**
  - Relaxation training
  - Physical exercise programs
  - Cognitive rehabilitation (individual and group)
  - Brain-training programs
  - EEG-based biofeedback
- However, no single treatment is considered a standard.

# Conclusion



# Conclusion

- Overall progress in cancer has led to greater focus on QoL in survivorship
- Cognitive *symptoms* are common during and after cancer treatment
- Research has identified cognitive impairment (particularly in chemotherapy), however significant questions remain (case definition, treatment, pathogenesis).
- There is no clinical definition of CRCI and no current standard therapy.
- Nevertheless, cognitive symptoms remain an important detractor from QoL.

# References

- Survival | Cancer Trends Progress Report. Accessed April 20, 2024. <https://progressreport.cancer.gov/after/survival>
- Cancer Treatment & Survivorship Facts & Figures 2022-2024. Accessed April 21, 2024. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/2022-cancer-treatment-and-survivorship-fandf-acf.pdf>
- Lai-Kwon J, Heynemann S, Hart NH, et al. Evolving Landscape of Metastatic Cancer Survivorship: Reconsidering Clinical Care, Policy, and Research Priorities for the Modern Era. *JCO*. 2023;41(18):3304-3310. doi:[10.1200/JCO.22.02212](https://doi.org/10.1200/JCO.22.02212)
- Cancer Treatment & Survivorship Facts & Figures 2022-2024. Accessed April 21, 2024. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-treatment-and-survivorship-facts-and-figures/2022-cancer-treatment-and-survivorship-fandf-acf.pdf>
- Harvey PD. Domains of cognition and their assessment. *Dialogues Clin Neurosci*. 2019;21(3):227-237. doi:[10.31887/DCNS.2019.21.3/pharvey](https://doi.org/10.31887/DCNS.2019.21.3/pharvey)
- American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders : DSM-5-TR*. Fifth edition, Text Revision (DSM-5-TR). Arlington, VA : American Psychiatric Association; 2022. <https://doi.org/10.1176/appi.books.9780890425787>
- Christian Bjerre-Real, James C. Root, Yesne Alici, Julia A. Kearney, and William S. Breitbart. *Screening for delirium in the cancer patient*. Breitbart W, et al. eds. Psycho-Oncology. Oxford University Press; 2021. doi:10.1093/med/9780190097653.001.0001
- Jean-Pierre P, Winters PC, Ahles TA, et al. Prevalence of self-reported memory problems in adult cancer survivors: a national cross-sectional study. *J Oncol Pract*. 2012;8(1):30-34. doi:[10.1200/JOP.2011.000231](https://doi.org/10.1200/JOP.2011.000231)
- Lange M, Licaj I, Clarisse B, et al. Cognitive complaints in cancer survivors and expectations for support: Results from a web-based survey. *Cancer Med*. 2019;8(5):2654-2663. doi:[10.1002/cam4.2069](https://doi.org/10.1002/cam4.2069)
- Dhillon HM, Tannock IF, Pond GR, Renton C, Rourke SB, Vardy JL. Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy. *J Cancer Surviv*. 2018;12(2):178-185. doi:[10.1007/s11764-017-0656-6](https://doi.org/10.1007/s11764-017-0656-6)
- Ganz PA, Kwan L, Castellon SA, et al. Cognitive Complaints After Breast Cancer Treatments: Examining the Relationship With Neuropsychological Test Performance. *J Natl Cancer Inst*. 2013;105(11):791-801. doi:[10.1093/jnci/djt073](https://doi.org/10.1093/jnci/djt073)

# References

- Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. *J Clin Oncol*. 2012;30(30):3675-3686. doi:[10.1200/JCO.2012.43.0116](https://doi.org/10.1200/JCO.2012.43.0116)
- McGinty HL, Phillips KM, Jim HSL, et al. Cognitive Functioning in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. *Support Care Cancer*. 2014;22(8):2271-2280. doi:[10.1007/s00520-014-2285-1](https://doi.org/10.1007/s00520-014-2285-1)
- Lange M, Joly F, Vardy J, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. *Ann Oncol*. 2019;30(12):1925-1940. doi:[10.1093/annonc/mdz410](https://doi.org/10.1093/annonc/mdz410)
- Tan BBJW, Chua SKK, Soh QY, Chan LL, Tan EK. Chimeric antigen receptor (CAR) T therapy and cognitive functions. *J Neurol Sci*. 2023;444:120495. doi:[10.1016/j.jns.2022.120495](https://doi.org/10.1016/j.jns.2022.120495)
- Ahles TA, Saykin AJ, McDonald BC, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. *Breast Cancer Res Treat*. 2008;110(1):143-152. doi:[10.1007/s10549-007-9686-5](https://doi.org/10.1007/s10549-007-9686-5)
- Apple AC, Schroeder MP, Ryals AJ, et al. Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. *Neuroimage Clin*. 2018;20:110-118. doi:[10.1016/j.nicl.2018.07.010](https://doi.org/10.1016/j.nicl.2018.07.010)
- Koppelmans V, de Ruiter MB, van der Lijn F, et al. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. *Breast Cancer Res Treat*. 2012;132(3):1099-1106. doi:[10.1007/s10549-011-1888-1](https://doi.org/10.1007/s10549-011-1888-1)
- Menning S, de Ruiter MB, Veltman DJ, et al. Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. *PLoS One*. 2017;12(3):e0171724. doi:[10.1371/journal.pone.0171724](https://doi.org/10.1371/journal.pone.0171724)
- Karschnia P, Parsons MW, Dietrich J. Pharmacologic management of cognitive impairment induced by cancer therapy. *Lancet Oncol*. 2019;20(2):e92-e102. doi:[10.1016/S1470-2045\(18\)30938-0](https://doi.org/10.1016/S1470-2045(18)30938-0)
- Cognitive function after cancer and cancer treatment - UpToDate. Accessed April 17, 2024. [https://www.uptodate.com/contents/cognitive-function-after-cancer-and-cancer-treatment?search=cancer%20related%20cognitive%20impairment&source=search\\_result&selectedTitle=1%7E150&usage\\_type=default&display\\_rank=1#topicContent](https://www.uptodate.com/contents/cognitive-function-after-cancer-and-cancer-treatment?search=cancer%20related%20cognitive%20impairment&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1#topicContent)